Endobronchial Treatment of Carcinoid Tumors of the Lung

Levent Dalar1  Cengiz Ozdemir2  Yasin Abul3  Sinem Nedime Sokucu2  Levent Karasulu2  Halide Nur Urer2  Sedat Altin2

1Bilim University Faculty of Medicine, Department of Pulmonary Medicine, Istanbul, Turkey
2Yedikule Chest Diseases and Thoracic Surgery Teaching Hospital, Istanbul, Turkey
3KTU Faculty of Medicine, Department of Pulmonary Medicine, Trabzon, Turkey


Abstract

Background Bronchial carcinoid tumors are known as low-grade malignancies. Surgery has been proposed as the best treatment of choice for lung carcinoids. However, less invasive treatment approaches may be considered due to low-grade malignancy potential of such tumors. The aim of this study was to review the results of endobronchial treatments of carcinoid tumors of the lung and to compare with the outcome after surgery.

Methods Initial complete tumor eradication with an endobronchial treatment was attempted for 29 patients. Diode laser or argon plasma coagulation was used during these treatments. Cryotherapy or laser treatments were applied consecutively in patients for whom there was good bronchoscopic visualization of the distal and basal tumor margins and no evidence of bronchial wall involvement. Surgery was performed in cases of atypical carcinoid and in cases of nonvisualization of the basal and distal part of the tumor.

Results Overall, 29 patients have been included (median age 58 years; range, 23–77 years). Median follow-up has been 49 months (range, 22–94 months). A total of 24 patients (69%) had typical carcinoid tumor, 5 patients (31%) had atypical carcinoid tumor. Initial endobronchial treatment provided complete tumor eradication in 21 of 29 patients (72%). Of the eight other patients (28%), two were atypical carcinoids, and underwent surgical treatment. There was no tumor-related death and no recurrence during the follow-up in both groups. There was no difference for survival or recurrence between the surgical and the endobronchial treatment group of patients (p > 0.05).

Conclusion Endobronchial treatment may be considered as safe, effective treatment for typical carcinoid tumors in the central airways. Addition of initial endobronchial treatment had no negative effect on the surgical outcome.

Introduction

Bronchial carcinoid tumors are rarely seen neuroendocrine tumors accounting for more than 1 to 5% of all lung tumors and approximately 20 to 30% of all carcinoid tumors.1–3 The majority of these tumors originated from the proximal airways and most of them are symptomatic with obstructing symptoms or hemoptysis due to the tumor’s hypervascularity.4 Bronchial
carcinoid tumors are mainly classified into two groups as typical and atypical bronchial carcinoids. Typical bronchial carcinoids have a good prognosis with a 10-year survival rate of 90% compared with the atypical carcinoids that have a greater rate of metastasis and recurrence with a 10-year survival below 60%. Generally, for patients with bronchial carcinoids surgical treatment has been the preferred approach with a 5-year survival rate of 95% after surgical treatment. Endobronchial treatment with laser or cryotherapy has been reported as an alternative to surgical treatment in selected patients with bronchial carcinoid tumors in individual cases. However, there have been a limited number of studies comparing endobronchial treatment with surgical treatment of bronchial carcinoids in large series, particularly with the use of cryotherapy. The aim of the present study was to review the results of endobronchial treatments including laser and cryotherapy and to compare endobronchial treatments with surgical treatment for the bronchial carcinoids.

**Patients and Methods**

The present study was designed as a retrospective cohort study in which all the data were retrospectively reviewed for the patients referred to the interventional pulmonology unit for bronchial carcinoid tumors between October 2006 and October 2012.

Initial complete tumor eradication by endobronchial treatment was attempted for 29 patients to improve the presurgical state with adequate tissue samples for histological classification of tumor, and to provide the minimal possible extensive parenchymal resection. Screening and staging procedures were done by contrast-enhanced computer tomography (CT) for all the study patients before any therapeutic intervention.

In studies with a retrospective analysis of standard diagnostic data, no ethical statement is needed in Turkey. Diode laser or argon plasma coagulation (APC) was used during endobronchial treatment. A diode laser operating at a wavelength in 980 nm with 4 to 25 W, in a pulsed mode (Biolitec, Ceralas D 25; Jena, Germany) was used for the endobronchial treatment. APC (40 W, blended mode-continuous flow) was performed using a device manufactured by ERBE Elektromedizin GmbH, (Tübingen, Germany). Standardized protocols for appropriate power selections were used in accordance with the manufacturer's recommendations.

Cryotherapy and laser treatment was applied consecutively in patients who had complete bronchoscopic visualization of the distal and basal tumor margins and no evidence of bronchial wall involvement. Cryotherapy was performed using the ERBE KRYO system (Elektromedizin GmbH). Treatment of lesions was performed according to the method described previously. Five cycles of freezing for 20 seconds were used for the entire tumor surface, tumor base, and a marginal area of 5 mm of normal mucosa around the tumor. The distance between two adjacent applications of the cryoprobe was approximately 5 mm providing sufficient depth of wall penetration. We performed two additional monthly cryotherapies after initial bronchoscopic excision of the tumor.

Endobronchial treatment was applied as a primary treatment modality for the patients having a strictly endoluminal disease which was previously defined as readily accessible to curative bronchoscopic therapy without thickening of the bronchial wall, an absence of lymph node invasion based on standard CT criteria and complete excision of the lesion if the tumor was strictly endoluminal and there was an absence of nodal enlargement.

All the patients were intubated by a rigid bronchoscope (Efer Endoscopy, La Ciotat, France) under intravenous general anesthesia using standard techniques and mechanical debridement was performed when necessary.

Bronchoscopic follow-up was done by radial probe endobronchial ultrasonography (Olympus EVExera II, EU-ME1, Tokyo, Japan) and autofluorescence bronchoscopy (LIFE-Lung, Xillix Technologies, Vancouver, Canada) after the endobronchial treatment. Surgery was performed in cases of atypical carcinoid and nonvisualization of the tumor base after endobronchial treatment and these have been called extraluminal tumor growths. The follow-up period was 49 months. The follow-up bronchoscopies were done at the 1st, 3rd, 6th month and at the end of the 1st year. After the 1 year follow-up period, bronchoscopies were done every 6 months.

**Results**

Overall, 29 patients, 17 of them females, have been included in the study (median age 58 years; range, 23–77 years). Median follow-up was 49 months (range, 22–94 months). A total of 24 patients (69%) had typical carcinoid tumor and 5 patients (21%) had atypical carcinoid tumor. Initial endobronchial treatment (Fig. 1) provided complete tumor eradication in 21 of the 29 patients (72%). Of the remaining 8 of the 29 patients (28%), 2 were atypical and underwent surgical treatment (Table 1). One patient who was operated for atypical carcinoid died 45 days after the operation due to sepsis. One operated case died due to ovarian carcinoma during the 45 months of follow-up period. Otherwise there was no tumor-related death and no recurrence during the follow-up period in either group of surgical treatment and/or in the group with endobronchial treatment. There was no difference in survivals or recurrences between the surgical and the endobronchial treatment groups (p > 0.05). Three patients in the atypical carcinoid group were given the endobronchial treatment. Symptomatic patients were 17 of the 29 patients (59%). The most common signs and symptoms of patients with bronchial carcinoids were coughing (productive or not) in six cases (21%), sputum production in three cases (10%), dyspnea in ten (35%), chest pain in five (17%), hemoptysis in two (7%), undefined 10%. The most common symptom was dyspnea in the present study population (Table 2).

Overall, 16 patients had right-sided bronchial carcinoid tumors and 13 patients had carcinoid tumors located in the left bronchial system.

A total of 13 patients were treated with APC as an initial endobronchial treatment. Among the 29 patients, 20 patients
were treated with the laser with curative intent. A total of 29 laser procedures (Fig. 2), 18 APC procedures, 38 cryotherapy procedures, 72 rigid bronchoscopy procedures, and 86 fiberoptic bronchoscopy procedures were performed during the initial treatments and during follow-up periods of the study population. Cryotherapy was applied for 15 patients to prevent recurrence as a treatment complimentary to the initial endobronchial treatment (Fig. 3). Two patients with bronchial carcinoids were treated solely with cryotherapy as a primary treatment modality without being any recurrence. Six patients had controlled hemorrhagic complications. There were no significant survival differences between patients treated with endobronchial treatment alone and the patients treated with surgical resection alone.

**Discussion**

Bronchoscopic resection of bronchial carcinoids has previously been regarded as acceptable only in patients with an inoperable condition. In the past, there seemed to be a consensus that surgical treatment of bronchial carcinoid tumors was the treatment choice for all the carcinoid tumors. However, bronchoscopic resection of bronchial carcinoid tumors has been represented as a successful modality for treatment of bronchial carcinoid tumors. Thus, at present there is no definitive consensus about endobronchial treatments of bronchial carcinoid tumors. Actually, a decision in favor of a surgical approach has been influenced by the proportion of patients having the type of atypical carcinoids of the lung. The present study confirms previous studies in which selected patients with intraluminal typical bronchial carcinoids were treated by a bronchoscopic approach but also two of our patients with atypical carcinoids and with no recurrence were resected by endobronchial treatment in the present study with acceptable survival rates during follow-up period. It has previously been reported that formerly resected atypical intrapulmonary carcinoid tumors having frequent endobronchial recurrences could be effectively treated by endobronchial laser application. In the present study, endobronchial cryotherapy was also used as an initial sole treatment modality and as a consecutive application to prevent recurrence. Those patients primarily treated with cryotherapy and those having consecutive cryotherapy applications had no recurrence during follow-up period. Others have reported that a series of 18 patients with typical bronchial carcinoids were treated bronchoscopically by cryotherapy and during a median follow-up of 55 months, only single local recurrence (5.5%) was noted 7 years after treatment. In the present study, there was no recurrence and no bronchial stenosis in the patients treated with cryotherapy during the 49 months of follow-up period. Endobronchial laser therapy has previously been reported as an effective method to treat strictly intraluminal

**Table 1** Clinical characteristics of the study population

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>Total number</th>
<th>APC and/or laser therapy and/or cryotherapy for curative intent</th>
<th>Surgery with preoperative endobronchial treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>29</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>12:17</td>
<td>10:11</td>
<td>2:6</td>
</tr>
<tr>
<td>Age (median, y)</td>
<td>58</td>
<td>59</td>
<td>48</td>
</tr>
<tr>
<td>Typical carcinoids</td>
<td>24</td>
<td>19</td>
<td>5</td>
</tr>
<tr>
<td>Atypical carcinoids</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Bilobectomy</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Lobectomy</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Sleeve lobectomy</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Abbreviation: APC, argon plasma coagulation.
16,17,20,21 Laser application was also used in the present study population as an endobronchial treatment of bronchial carcinoids. There was no recurrence during the 49 months of follow-up period in patients treated with laser application in the present study. Previous studies both with laser and cryotherapy and their bronchoscopic features are summarized in Table 3. Accurate assessment of the tumor extension is a very important step in selecting patients with bronchial carcinoids who are candidates for endobronchial treatment. It is also important to determine the effectiveness of endobronchial treatments compared with standard treatments. High-resolution tomography, endobronchial ultrasonography, and autofluorescence bronchoscopy can be used both for assessing extension of the tumor before the treatment and for the determining effectiveness of endobronchial treatment during follow-up.9,19 High-resolution tomography, endobronchial ultrasonography, and autofluorescence bronchoscopy (Fig. 4) were used in the present study to follow-up the study population. Lung carcinoid tumors have usually been described as tumors with low grade of fluorodeoxyglucose (FDG) uptake due to tumors’ low metabolism and slow growth. Therefore, FDG-positron emission tomography (PET) has been known to have a reduced sensitivity for carcinoids and a limited role in the diagnosis of those lesions. Some controversial results have been proposed on the diagnostic accuracy of FDG-PET for bronchial carcinoids. However, there is some evidence reporting the use of PET with analogues of somatostatin including DOTA-TOC, DOTA-NOC, or DOTA-TATE labeled with gallium-68 (Ga-68) in pulmonary carcinoids.22 Ga68-DOTA-TOC PET/CT is a useful thoracic imaging technique to evaluate pulmonary carcinoids with sensitivity of 96 and 100% specific whereas 18F-FDG PET/CT scan provides low sensitivity and specificity to differentiate pulmonary carcinoids from other lung malignancies.23 Magnetic resonance imaging (MRI) usually does not provide more efficient knowledge than CT, but dynamic contrast-enhanced MRI may be useful to differentiate peripheral carcinoids that have small contrast-enhancement from pulmonary vessels, or to define vascular involvement by a central lesion.24 When compared with the pathological size of the lesion, endobronchial ultrasound measurements were reported as more accurate than high-resolution CT measurements.25

Although bronchial carcinoids have a low potential for malignancy, posttreatment surveillance of patients with bronchial carcinoid tumors is necessary because of the recurrence potential of the tumors after initial treatment. The optimal posttreatment surveillance strategy is not well defined, and there is no consensus about follow-up of bronchial carcinoids.26

The main limitation of the present study is its retrospective design. The second limitation is that the present study is not a randomized controlled study and the third is the fact that its conclusions are based on a single center experience. Although the study includes moderate number of patients for such a rare tumor, it could be considered that the power of the present study is limited. Studies comparing endobronchial treatment with surgical treatment are limited in the literature.21 Long-term outcomes of bronchoscopically resected endobronchial typical carcinoid tumors has been reported as acceptable.20,27,28 There were no significant differences between the patients receiving endobronchial treatment and patients receiving surgical therapy in the present study. However, the study group of the patients with surgical treatment is limited in number. It should be stressed that treatment of two atypical bronchial carcinoids with endobronchial treatment without any recurrence is important from the point of using of endobronchial treatment in selected bronchial carcinoids.

### Table 2 Symptoms of the patients with bronchial carcinoids at the time of diagnosis

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyspnea</td>
<td>10 (35)</td>
</tr>
<tr>
<td>Cough</td>
<td>6 (21)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5 (17)</td>
</tr>
<tr>
<td>Sputum</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Hemoptysis</td>
<td>2 (7)</td>
</tr>
<tr>
<td>Undefined</td>
<td>3 (10)</td>
</tr>
</tbody>
</table>

**Fig. 2** A 53-year-old male patient had a history of bronchoscopic resection of carcinoid tumors located in the intermediate bronchus. Minimal residual tissue and view of laser ablation are seen. Follow-up period is 67 months without any recurrence.
Conclusions

Endobronchial treatment is a potentially more tissue-protecting alternative than early surgical resection in patients with intraluminally located carcinoids. The current study has a retrospective design and no randomization has been done. In spite of these limitations, endobronchial laser treatment and cryotherapy may be considered as safe and effective treatment modalities in the treatment of carcinoid tumors in the central airways with intraluminal tumor growth. Addition of initial endobronchial treatment had no negative effect on surgical treatment outcome.

Fig. 3  (a) Atypical bronchial carcinoids within right main bronchus, showing the widespread nodularity within the proximal part of the right main bronchus. (b) Endobronchial view of the lesion is seen after 1 year consecutive cryotherapy.

Table 3  Literature studies including endobronchial treatment of bronchial carcinoids with curative intent

<table>
<thead>
<tr>
<th>Clinical studies</th>
<th>Number of study population for endobronchial treatment</th>
<th>Follow-up time (median/mo)</th>
<th>Cure rate (%)</th>
<th>Bronchoscopic technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutedja et al</td>
<td>11</td>
<td>70</td>
<td>55</td>
<td>RB + laser or mechanical under GA</td>
</tr>
<tr>
<td>Cavaliere et al</td>
<td>38</td>
<td>24</td>
<td>92</td>
<td>RB + laser under GA</td>
</tr>
<tr>
<td>van Boxem et al</td>
<td>19</td>
<td>29</td>
<td>73</td>
<td>RB + laser under GA</td>
</tr>
<tr>
<td>Luckraz et al</td>
<td>28</td>
<td>105</td>
<td>94</td>
<td>RB + MR under GA</td>
</tr>
<tr>
<td>Bertoletti et al</td>
<td>18</td>
<td>55</td>
<td>96</td>
<td>RB + cryotherapy under GA (14 patients)</td>
</tr>
<tr>
<td>Fuks et al</td>
<td>10</td>
<td>24</td>
<td>100</td>
<td>FB + cryotherapy (4 patients)</td>
</tr>
<tr>
<td>Neyman et al</td>
<td>25</td>
<td>36</td>
<td>94</td>
<td>RB + laser under GA</td>
</tr>
<tr>
<td>Brokx et al</td>
<td>33</td>
<td>65</td>
<td>100</td>
<td>RB + FB + Nd:YAG laser or electrocautery under GA</td>
</tr>
<tr>
<td>The present study</td>
<td>29</td>
<td>49</td>
<td>100</td>
<td>RB + laser ±cryotherapy under GA</td>
</tr>
</tbody>
</table>

Abbreviations: CS, conscious sedation; FB, flexible bronchoscopy; GA, general anesthesia; MR, mechanical resection; RB, rigid bronchoscopy.

Fig. 4  (a) Endobronchial view of atypical carcinoids with nodularity located in right lower lobe bronchus is seen. (b) Autofluorescence bronchoscopic view of the same lesion is demonstrated. (c) Neuroendocrine tumor cells that shows nuclear atypical pattern. Hematoxylin and eosin stain, ×400.
Acknowledgment
The authors thank Prof. R. W. Guillery from Oxford University for the correction of English in the article.

References